Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2685223 | 0.81 | HTT (0.47) | HTTTDP1 | |
| SCHEMBL2767676 | 0.76 | CYP3A4 (0.31) | TDP1 | |
| SCHEMBL3462831 | 0.72 | HTT (0.33) | HTTTDP1 | |
| SCHEMBL220664 | 0.71 | — | — | |
| SCHEMBL1720012 | 0.71 | KMT2A (0.30) | — | |
| SCHEMBL2890991 | 0.70 | — | — | |
| SCHEMBL6816414 | 0.69 | — | — | |
| SCHEMBL4858324 | 0.69 | CYP3A4 (0.33) | TDP1 | |
| SCHEMBL8089743 | 0.68 | APP (0.44) | HTTTDP1 | |
| SCHEMBL77754 | 0.67 | CA1 (0.39) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2017-10-05 | — | — | US | claimed |
| EP-3187486-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | Amorepacific Corporation (KR) | 2017-07-05 | — | — | EP | claimed |
| EP-2507243-B1 | SPIROINDOLINONE PYRROLIDINES | HOFFMANN LA ROCHE (CH) | 2015-06-10 | — | — | EP | claimed |
| EP-2507243-A1 | SPIROINDOLINONE PYRROLIDINES | F. Hoffmann-La Roche AG (CH) | 2012-10-10 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| EP-3187486-B1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORP (KR) | 2023-10-18 | — | — | EP | disclosed |
| US-10696611-B2 | Adamantane derivative compound | AMOREPACIFIC CORPORATION (KR) | 2020-06-30 | — | — | US | disclosed |
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | AMOREPACIFIC CORPORATION (KR) | 2017-10-05 | — | — | US | disclosed |
| EP-1844020-B1 | HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS | EXELIXIS INC (US) | 2017-09-06 | — | — | EP | disclosed |
| EP-3187486-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | Amorepacific Corporation (KR) | 2017-07-05 | — | — | EP | disclosed |
| EP-1137632-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1137647-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1137633-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034268-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034238-A1 | THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
| WO-2000034237-A2 | ACETAMIDE AND SUBSTITUTED ACETAMIDE-CONTAINING THIOUREA INHIBITORS OF HERPES VIRUSES | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696611-B2 | Adamantane derivative compound | ADAM8, BACE1, CYP17A1 | HTT 1830/4885TDP1 1151/4885 |
| US-20170283347-A1 | NOVEL ADAMANTANE DERIVATIVE COMPOUND | ADAM8, CYP17A1, ADAM10 | HTT 2081/4885TDP1 1225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.